Mohammad Abbasinazari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammad Abbasinazari has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
Saeed Abdi
Gastroenterology and Liver Diseases Research center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 shared publicationsAmir Farrokhian
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications- Amir Sadeghi
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences Tehran Iran
3 shared publications Yunes Panahi
Baqiyatallah Univ Med Sci, Chem Injuries Res Ctr, Tehran, Iran
3 shared publicationsAli Pirsalehi
Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications- Amir Farrokhian
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (11)
Effect of Melatonin on 24‐Hour Urinary Protein Excretion and Sleep Quality in Patients With Stage 3–4 Chronic Kidney Disease: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial
Background and Aims: Proteinuria is an established marker of renal injury and is closely associated with adverse outcomes in chronic kidney disease (CKD). Melatonin has attracted interest as a potential renoprotective agent because of its antioxidant, anti‐inflammatory, and regulatory effects on several pathways implicated in kidney injury. However, clinical data regarding its effects on proteinuria in patients with non‐dialysis CKD are limited. This trial investigated whether melatonin supplementation alters 24‐h urinary protein excretion in adults with stage 3–4 CKD. Methods: We conducted a 12‐week, randomized, double‐blind, placebo‐controlled clinical trial in adults with stage 3–4 CKD and persistent proteinuria. Seventy‐three participants were allocated in a 1:1 ratio to receive either oral melatonin (3 mg at bedtime) or a matching placebo. The prespecified primary endpoint was the change in 24‐h urinary protein excretion between baseline and week 12. Secondary assessments included renal function, blood pressure, sleep quality, metabolic and laboratory parameters, and treatment safety. Results: A reduction in 24‐h urinary protein excretion was observed in both treatment groups. The mean reduction was 52.45 ± 128.19 mg/day with melatonin and 28.69 ± 82.59 mg/day with placebo, yielding a between‐group difference of −23.76 mg/day (95% CI, −74.08 to 26.56; p = 0.92). Serum creatinine and estimated glomerular filtration rate remained largely stable during follow‐up. Compared with placebo, melatonin was associated with a significant reduction in total cholesterol. Sleep quality also showed a statistically significant difference in the change in PSQI score between groups, with mean changes of −0.18 ± 0.84 and −0.69 ± 1.06 in the melatonin and placebo groups, respectively ( p = 0.047). No treatment‐related serious adverse events were observed. Conclusion: In adults with stage 3–4 CKD, 12 weeks of melatonin supplementation at 3 mg nightly did not demonstrate a clinically meaningful reduction in 24‐h urinary protein excretion compared with placebo. Although the point estimate favored melatonin, the confidence interval was compatible with both a modest benefit and no treatment effect. Melatonin was generally well tolerated and was associated with modest changes in selected metabolic and sleep‐related outcomes. Larger, multicenter trials with longer follow‐up and adequate statistical power are needed to determine whether melatonin has clinically relevant renal effects in specific CKD populations. Trial Registration: This clinical trial was registered in the Iranian Registry of Clinical Trials (IRCT No. IRCT20160412027346N12)
- 29 October 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (11)
Open AccessEffect of Melatonin on 24‐Hour Urinary Protein Excretion and Sleep Quality in Patients With Stage 3–4 Chronic Kidney Disease: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial
Background and Aims: Proteinuria is an established marker of renal injury and is closely associated with adverse outcomes in chronic kidney disease (CKD). Melatonin has attracted interest as a potential renoprotective agent because of its antioxidant, anti‐inflammatory, and regulatory effects on several pathways implicated in kidney injury. However, clinical data regarding its effects on proteinuria in patients with non‐dialysis CKD are limited. This trial investigated whether melatonin supplementation alters 24‐h urinary protein excretion in adults with stage 3–4 CKD. Methods: We conducted a 12‐week, randomized, double‐blind, placebo‐controlled clinical trial in adults with stage 3–4 CKD and persistent proteinuria. Seventy‐three participants were allocated in a 1:1 ratio to receive either oral melatonin (3 mg at bedtime) or a matching placebo. The prespecified primary endpoint was the change in 24‐h urinary protein excretion between baseline and week 12. Secondary assessments included renal function, blood pressure, sleep quality, metabolic and laboratory parameters, and treatment safety. Results: A reduction in 24‐h urinary protein excretion was observed in both treatment groups. The mean reduction was 52.45 ± 128.19 mg/day with melatonin and 28.69 ± 82.59 mg/day with placebo, yielding a between‐group difference of −23.76 mg/day (95% CI, −74.08 to 26.56; p = 0.92). Serum creatinine and estimated glomerular filtration rate remained largely stable during follow‐up. Compared with placebo, melatonin was associated with a significant reduction in total cholesterol. Sleep quality also showed a statistically significant difference in the change in PSQI score between groups, with mean changes of −0.18 ± 0.84 and −0.69 ± 1.06 in the melatonin and placebo groups, respectively ( p = 0.047). No treatment‐related serious adverse events were observed. Conclusion: In adults with stage 3–4 CKD, 12 weeks of melatonin supplementation at 3 mg nightly did not demonstrate a clinically meaningful reduction in 24‐h urinary protein excretion compared with placebo. Although the point estimate favored melatonin, the confidence interval was compatible with both a modest benefit and no treatment effect. Melatonin was generally well tolerated and was associated with modest changes in selected metabolic and sleep‐related outcomes. Larger, multicenter trials with longer follow‐up and adequate statistical power are needed to determine whether melatonin has clinically relevant renal effects in specific CKD populations. Trial Registration: This clinical trial was registered in the Iranian Registry of Clinical Trials (IRCT No. IRCT20160412027346N12)
- Open Access
- 20 May 2026
- Published by Brieflands in Iranian Journal of Pharmaceutical Research
- Vol. 25 (1) , e170096
Adjunct Low-Dose Dexmedetomidine for Sedation in Mechanically Ventilated Children: An Exploratory Randomized Trial
Background: Effective sedation in the pediatric intensive care unit (PICU) is complicated by the adverse effects of benzodiazepines and opioids. Dexmedetomidine may provide a benzodiazepine-sparing alternative with distinct pharmacologic properties. Objectives: We hypothesized that adjunct, fixed low-dose, no-bolus dexmedetomidine would reduce midazolam and fentanyl exposure per ventilator-day in mechanically ventilated children. Methods: In a triple-blind randomized controlled trial, 60 mechanically ventilated patients aged 1 month to 12 years were randomized to standard sedation (continuous midazolam and fentanyl) plus low-dose dexmedetomidine (a fixed-rate continuous infusion at 0.2 µg/kg/h without a loading bolus) or matched placebo (0.9% normal saline). In both groups, midazolam and fentanyl were titrated per protocol to achieve the target Richmond Agitation-Sedation Scale (RASS) level. Results: Among 60 randomized children, adjunct fixed low-dose dexmedetomidine did not reduce the prespecified primary outcome of fentanyl or midazolam exposure per ventilator-day. Median fentanyl exposure per ventilator-day was 70.0 µg·kg-1·day-1 in the control group and 90.6 µg·kg-1·day-1 in the dexmedetomidine group; median midazolam exposure per ventilator-day was 7.0 mg·kg-1·day-1 and 9.1 mg·kg-1·day-1, respectively. Neither primary comparison remained statistically significant after Holm correction. In an unadjusted secondary analysis, the median time to first successful extubation was 6 days in the dexmedetomidine group and 15 days in the control group. This finding was exploratory and was not confirmed by the prespecified competing-risk or longitudinal ventilation analyses. Conclusions: Adjunct fixed low-dose dexmedetomidine without a loading bolus did not reduce fentanyl or midazolam exposure per ventilator-day. Early sedative-analgesic exposure was higher with dexmedetomidine, and the apparent early-extubation signal was exploratory and was not confirmed by competing-risk or longitudinal analyses of ventilation.
- 20 May 2026
- Published by Brieflands in Iranian Journal of Pharmaceutical Research
- Vol. 25 (1) , e170096
Open AccessAdjunct Low-Dose Dexmedetomidine for Sedation in Mechanically Ventilated Children: An Exploratory Randomized Trial
Background: Effective sedation in the pediatric intensive care unit (PICU) is complicated by the adverse effects of benzodiazepines and opioids. Dexmedetomidine may provide a benzodiazepine-sparing alternative with distinct pharmacologic properties. Objectives: We hypothesized that adjunct, fixed low-dose, no-bolus dexmedetomidine would reduce midazolam and fentanyl exposure per ventilator-day in mechanically ventilated children. Methods: In a triple-blind randomized controlled trial, 60 mechanically ventilated patients aged 1 month to 12 years were randomized to standard sedation (continuous midazolam and fentanyl) plus low-dose dexmedetomidine (a fixed-rate continuous infusion at 0.2 µg/kg/h without a loading bolus) or matched placebo (0.9% normal saline). In both groups, midazolam and fentanyl were titrated per protocol to achieve the target Richmond Agitation-Sedation Scale (RASS) level. Results: Among 60 randomized children, adjunct fixed low-dose dexmedetomidine did not reduce the prespecified primary outcome of fentanyl or midazolam exposure per ventilator-day. Median fentanyl exposure per ventilator-day was 70.0 µg·kg-1·day-1 in the control group and 90.6 µg·kg-1·day-1 in the dexmedetomidine group; median midazolam exposure per ventilator-day was 7.0 mg·kg-1·day-1 and 9.1 mg·kg-1·day-1, respectively. Neither primary comparison remained statistically significant after Holm correction. In an unadjusted secondary analysis, the median time to first successful extubation was 6 days in the dexmedetomidine group and 15 days in the control group. This finding was exploratory and was not confirmed by the prespecified competing-risk or longitudinal ventilation analyses. Conclusions: Adjunct fixed low-dose dexmedetomidine without a loading bolus did not reduce fentanyl or midazolam exposure per ventilator-day. Early sedative-analgesic exposure was higher with dexmedetomidine, and the apparent early-extubation signal was exploratory and was not confirmed by competing-risk or longitudinal analyses of ventilation.
- Open Access
- 4 May 2026
- Published by Brieflands in Iranian Journal of Pharmaceutical Research
- Vol. 25 (1) , e168523
Evaluation of Mesna Co-administration in the Management of Acute Pancreatitis: A Pilot Randomized Clinical Trial
Background: The use of antioxidants has been shown to mitigate the symptoms of acute pancreatitis (AP) and improve associated biomarkers. Objectives: In light of the antioxidant properties of mesna, this pilot study was undertaken to determine whether the addition of mesna to standard treatment for AP offers superior outcomes compared with standard treatment alone. Methods: In a randomized open-label pilot trial, patients diagnosed with AP were enrolled in the study. Intravenous mesna at a dose of 400 mg/day was administered for 7 days. Clinical indicators, including the Harmless Acute Pancreatitis Score (HAPS), amylase, lipase, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and malondialdehyde (MDA), were measured at baseline and after the 7-day treatment period. Results: Although MDA levels significantly decreased in the group receiving mesna combined with standard therapy compared with the group receiving standard therapy alone after 7 days (P = 0.01), no significant differences were observed between the 2 groups in terms of HAPS, amylase, lipase, CRP, or ESR. Conclusions: These findings suggest that the addition of mesna at a daily dose of 400 mg did not influence the overall outcome of AP after 7 days. Further large-scale studies with varying doses and durations of mesna administration are recommended.
- 4 May 2026
- Published by Brieflands in Iranian Journal of Pharmaceutical Research
- Vol. 25 (1) , e168523
Open AccessEvaluation of Mesna Co-administration in the Management of Acute Pancreatitis: A Pilot Randomized Clinical Trial
Background: The use of antioxidants has been shown to mitigate the symptoms of acute pancreatitis (AP) and improve associated biomarkers. Objectives: In light of the antioxidant properties of mesna, this pilot study was undertaken to determine whether the addition of mesna to standard treatment for AP offers superior outcomes compared with standard treatment alone. Methods: In a randomized open-label pilot trial, patients diagnosed with AP were enrolled in the study. Intravenous mesna at a dose of 400 mg/day was administered for 7 days. Clinical indicators, including the Harmless Acute Pancreatitis Score (HAPS), amylase, lipase, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and malondialdehyde (MDA), were measured at baseline and after the 7-day treatment period. Results: Although MDA levels significantly decreased in the group receiving mesna combined with standard therapy compared with the group receiving standard therapy alone after 7 days (P = 0.01), no significant differences were observed between the 2 groups in terms of HAPS, amylase, lipase, CRP, or ESR. Conclusions: These findings suggest that the addition of mesna at a daily dose of 400 mg did not influence the overall outcome of AP after 7 days. Further large-scale studies with varying doses and durations of mesna administration are recommended.
- 1 August 2025
- Published by Wiley in Musculoskeletal Care
- Vol. 23 (3) , e70179
Prevalence of Depression in Elderly Patients With Osteoarthritis: A Cross‐Sectional Study
Objectives: This study aimed to investigate the prevalence of Major Depressive Disorder (MDD) among elderly patients with osteoarthritis (OA) and explore the association between MDD and OA severity. Additionally, the impact of depression on OA prognosis and treatment outcomes was examined.Methods: A cross‐sectional study was conducted at a Rehabilitation Clinic from April 2022 to December 2023, including patients aged 50 years and older with OA. Written informed consent was obtained from all participants before enrolment. OA severity was classified using the Kellgren and Lawrence grading system as Grade 1 (n = 20,25.6%), Grade 2 (n = 42,53.8%), and Grade 3 (n = 16,20.5%). Depression prevalence and severity were assessed using the Hamilton Depression Rating Scale.Results: 78 OA patients (mean age: 60.35 ± 7.28 years) participated. Depression was prevalent in 83.3%, with a mean depression score of 18.14 ± 8.69. The most frequently reported symptoms were somatic anxiety, psychiatric anxiety, and depressed mood. Depression was more common and severe in females, particularly housewives. Patients with concurrent knee and spine OA exhibited greater depression severity than those with a single affected site. Notably, depression scores significantly improved following the OA treatment (p‐value: 0.045).Conclusion: The high prevalence of depression among elderly OA patients highlights the need for routine depression screening and management in OA care. Given the significant association between depression severity and OA type, addressing mental health concerns may enhance treatment outcomes and quality of life in this population. Future research should further investigate the long‐term impact of depression on OA prognosis and treatment response.
- 1 August 2025
- Published by Wiley in Musculoskeletal Care
- Vol. 23 (3) , e70179
Prevalence of Depression in Elderly Patients With Osteoarthritis: A Cross‐Sectional Study
Objectives: This study aimed to investigate the prevalence of Major Depressive Disorder (MDD) among elderly patients with osteoarthritis (OA) and explore the association between MDD and OA severity. Additionally, the impact of depression on OA prognosis and treatment outcomes was examined.Methods: A cross‐sectional study was conducted at a Rehabilitation Clinic from April 2022 to December 2023, including patients aged 50 years and older with OA. Written informed consent was obtained from all participants before enrolment. OA severity was classified using the Kellgren and Lawrence grading system as Grade 1 (n = 20,25.6%), Grade 2 (n = 42,53.8%), and Grade 3 (n = 16,20.5%). Depression prevalence and severity were assessed using the Hamilton Depression Rating Scale.Results: 78 OA patients (mean age: 60.35 ± 7.28 years) participated. Depression was prevalent in 83.3%, with a mean depression score of 18.14 ± 8.69. The most frequently reported symptoms were somatic anxiety, psychiatric anxiety, and depressed mood. Depression was more common and severe in females, particularly housewives. Patients with concurrent knee and spine OA exhibited greater depression severity than those with a single affected site. Notably, depression scores significantly improved following the OA treatment (p‐value: 0.045).Conclusion: The high prevalence of depression among elderly OA patients highlights the need for routine depression screening and management in OA care. Given the significant association between depression severity and OA type, addressing mental health concerns may enhance treatment outcomes and quality of life in this population. Future research should further investigate the long‐term impact of depression on OA prognosis and treatment response.
- Open Access
- 13 April 2025
- Published by Knowledge E DMCC in Journal of Pharmaceutical Care
The Role of Clinical Pharmacists in Mitigating Drug-Induced QTc Prolongation: A Cross-Sectional Study
Background: Drug-induced QTc prolongation represents the predominant cause of acquired long QTc syndrome. Pharmacists’ intervention, through the screening of at-risk patients and the provision of recommendations to prescribers for modifying drug regimens, may mitigate the adverse outcomes associated with this condition. This cross-sectional study aimed to evaluate the role of clinical pharmacists in reducing drug-induced acquired long QTc syndrome and mitigating the risk of progression toward life-threatening arrhythmias. Methods: We included hospitalized patients who were receiving at least two concomitant QT-prolonging medications, or one QT-prolonging medication along with a diagnosis of heart failure, myocardial infarction, or sepsis in the study over three months. Using the Tisdale risk score, we provided recommendations to the prescribing physician, and acceptance rates were recorded. Additionally, the rate of QTc prolongation was assessed in the patients. Results: The study was completed with 90 patients. The concomitant use of ondansetron and methadone was identified as the most common high-risk drug combination. A total of 56 pharmacist recommendations were made, with an estimated physician acceptance rate of 89%. Additionally, normalization of the QTc interval was observed in 14 out of 22 patients (63.6%) following pharmacists’ intervention. Conclusion: Clinical pharmacists are instrumental in the prevention of drug-induced long QTc syndrome among hospitalized patients.
- 13 April 2025
- Published by Knowledge E DMCC in Journal of Pharmaceutical Care
Open AccessThe Role of Clinical Pharmacists in Mitigating Drug-Induced QTc Prolongation: A Cross-Sectional Study
Background: Drug-induced QTc prolongation represents the predominant cause of acquired long QTc syndrome. Pharmacists’ intervention, through the screening of at-risk patients and the provision of recommendations to prescribers for modifying drug regimens, may mitigate the adverse outcomes associated with this condition. This cross-sectional study aimed to evaluate the role of clinical pharmacists in reducing drug-induced acquired long QTc syndrome and mitigating the risk of progression toward life-threatening arrhythmias. Methods: We included hospitalized patients who were receiving at least two concomitant QT-prolonging medications, or one QT-prolonging medication along with a diagnosis of heart failure, myocardial infarction, or sepsis in the study over three months. Using the Tisdale risk score, we provided recommendations to the prescribing physician, and acceptance rates were recorded. Additionally, the rate of QTc prolongation was assessed in the patients. Results: The study was completed with 90 patients. The concomitant use of ondansetron and methadone was identified as the most common high-risk drug combination. A total of 56 pharmacist recommendations were made, with an estimated physician acceptance rate of 89%. Additionally, normalization of the QTc interval was observed in 14 out of 22 patients (63.6%) following pharmacists’ intervention. Conclusion: Clinical pharmacists are instrumental in the prevention of drug-induced long QTc syndrome among hospitalized patients.
- Open Access
- 27 February 2025
- Published by Brieflands in Jundishapur Journal of Natural Pharmaceutical Products
- Vol. 20 (1)
A Randomized, Placebo-Controlled Study Investigating the Impact of α-pinene on Symptom Relief, Quality of Life and Inflammatory Markers in Individuals with Ulcerative Colitis
Background: Given the limited evidence on the efficacy of α-pinene, a herbal terpenoid, in the management of ulcerative colitis (UC), this clinical trial aims to investigate the effects of α-pinene compared to a placebo. Methods: Eligible UC patients were randomized to receive either α-pinene or a placebo, alongside their routine pharmacologic regimen, for two months. Quality of life (QoL) and disease severity were assessed using the Simple Clinical Colitis Activity Index Questionnaire (SCCAIQ) and the Crohn’s and UC Questionnaire-8 (CUCQ-8), respectively. Additionally, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were measured as inflammatory markers. Results: The QoL was significantly improved in the α-pinene group compared to the placebo group (P = 0.02). Several items of the CUCQ-8 also showed better outcomes in the α-pinene group. However, there were no significant differences in ESR and CRP levels between the two groups (P = 0.64 and P = 0.78, respectively). Conclusions: α-pinene may be considered as a dietary supplement to enhance QoL and alleviate several symptoms in patients with UC.
- 27 February 2025
- Published by Brieflands in Jundishapur Journal of Natural Pharmaceutical Products
- Vol. 20 (1)
Open AccessA Randomized, Placebo-Controlled Study Investigating the Impact of α-pinene on Symptom Relief, Quality of Life and Inflammatory Markers in Individuals with Ulcerative Colitis
Background: Given the limited evidence on the efficacy of α-pinene, a herbal terpenoid, in the management of ulcerative colitis (UC), this clinical trial aims to investigate the effects of α-pinene compared to a placebo. Methods: Eligible UC patients were randomized to receive either α-pinene or a placebo, alongside their routine pharmacologic regimen, for two months. Quality of life (QoL) and disease severity were assessed using the Simple Clinical Colitis Activity Index Questionnaire (SCCAIQ) and the Crohn’s and UC Questionnaire-8 (CUCQ-8), respectively. Additionally, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were measured as inflammatory markers. Results: The QoL was significantly improved in the α-pinene group compared to the placebo group (P = 0.02). Several items of the CUCQ-8 also showed better outcomes in the α-pinene group. However, there were no significant differences in ESR and CRP levels between the two groups (P = 0.64 and P = 0.78, respectively). Conclusions: α-pinene may be considered as a dietary supplement to enhance QoL and alleviate several symptoms in patients with UC.
- Open Access
- 15 February 2025
- Published by Brieflands in Iranian Journal of Pharmaceutical Research
- Vol. 24 (1)
Assessment of the Efficacy and Safety of Sublingual Melatonin on Symptom Severity, Quality of Life, and Sleep Disorders in Patients with Irritable Bowel Syndrome
Background: Previous studies have demonstrated the efficacy of melatonin in alleviating symptoms of irritable bowel syndrome (IBS) and improving quality of life (QoL). Objectives: Due to its superior bioavailability, this trial was designed to compare the effects of sublingual melatonin (SL melatonin) with a placebo in alleviating IBS symptoms, enhancing QoL, and addressing sleep disorders. Methods: The IBS patients were randomly assigned to receive either 3 mg of SL melatonin or a matching placebo for eight weeks. Participants completed the IBS symptom severity score (IBS-SSS), IBS-quality of life 34 items (IBS-QoL 34), and Pittsburgh Sleep Quality Index (PSQI) questionnaires immediately before and after the study period. Results: A total of 76 patients completed the trial over six months. The results indicated that the severity of IBS symptoms and QoL scores were significantly better in the SL melatonin group compared to the placebo group (P = 0.032 and P = 0.045, respectively). No participants withdrew from the trial due to serious side effects in either the SL melatonin or placebo groups. Conclusions: Sublingual melatonin may be administered to IBS patients as a complementary treatment to alleviate symptoms and improve QoL.
- 15 February 2025
- Published by Brieflands in Iranian Journal of Pharmaceutical Research
- Vol. 24 (1)
Open AccessAssessment of the Efficacy and Safety of Sublingual Melatonin on Symptom Severity, Quality of Life, and Sleep Disorders in Patients with Irritable Bowel Syndrome
Background: Previous studies have demonstrated the efficacy of melatonin in alleviating symptoms of irritable bowel syndrome (IBS) and improving quality of life (QoL). Objectives: Due to its superior bioavailability, this trial was designed to compare the effects of sublingual melatonin (SL melatonin) with a placebo in alleviating IBS symptoms, enhancing QoL, and addressing sleep disorders. Methods: The IBS patients were randomly assigned to receive either 3 mg of SL melatonin or a matching placebo for eight weeks. Participants completed the IBS symptom severity score (IBS-SSS), IBS-quality of life 34 items (IBS-QoL 34), and Pittsburgh Sleep Quality Index (PSQI) questionnaires immediately before and after the study period. Results: A total of 76 patients completed the trial over six months. The results indicated that the severity of IBS symptoms and QoL scores were significantly better in the SL melatonin group compared to the placebo group (P = 0.032 and P = 0.045, respectively). No participants withdrew from the trial due to serious side effects in either the SL melatonin or placebo groups. Conclusions: Sublingual melatonin may be administered to IBS patients as a complementary treatment to alleviate symptoms and improve QoL.
- Open Access
Efficacy of 2‐Mercaptoethane Sulfonate Sodium (MESNA) in the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Randomized Open Label Trial
Background and Aim: Oxidative stress has been considered a factor in the development of post‐endoscopic retrograde cholangiopancreatography pancreatitis (PEP). The present clinical trial evaluated whether adding intravenous mesna to rectal indomethacin could prevent or alleviate PEP.Methods: An open‐labeled clinical trial was done on 698 participants undergoing endoscopic retrograde cholangiopancreatography (ERCP). Eligible patients received 100 mg indomethacin suppository 30 min before undergoing ERCP. Randomly, the participants received 400 mg intravenous mesna or nothing 30 min before doing the procedure. The PEP incidence and degree were measured in the patients as the main outcome.Results: The total rate of PEP was equal to 13.7%. No significant difference was seen in the rate and severity of PEP between the mesna plus indomethacin and indomethacin alone arms (14% vs. 13.4%, respectively, p = 0.671). In high‐risk patients, PEP rate and severity were lower in the mesna plus indomethacin group compared with indomethacin alone group and the statistical analysis showed that the difference was significant (41.7% vs. 51.8%, respectively, p = 0.033).Conclusion: In high‐risk patients undergoing ERCP, a combination of intravenous mesna plus rectal indomethacin may decrease the PEP rate and severity.
Open AccessEfficacy of 2‐Mercaptoethane Sulfonate Sodium (MESNA) in the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Randomized Open Label Trial
Background and Aim: Oxidative stress has been considered a factor in the development of post‐endoscopic retrograde cholangiopancreatography pancreatitis (PEP). The present clinical trial evaluated whether adding intravenous mesna to rectal indomethacin could prevent or alleviate PEP.Methods: An open‐labeled clinical trial was done on 698 participants undergoing endoscopic retrograde cholangiopancreatography (ERCP). Eligible patients received 100 mg indomethacin suppository 30 min before undergoing ERCP. Randomly, the participants received 400 mg intravenous mesna or nothing 30 min before doing the procedure. The PEP incidence and degree were measured in the patients as the main outcome.Results: The total rate of PEP was equal to 13.7%. No significant difference was seen in the rate and severity of PEP between the mesna plus indomethacin and indomethacin alone arms (14% vs. 13.4%, respectively, p = 0.671). In high‐risk patients, PEP rate and severity were lower in the mesna plus indomethacin group compared with indomethacin alone group and the statistical analysis showed that the difference was significant (41.7% vs. 51.8%, respectively, p = 0.033).Conclusion: In high‐risk patients undergoing ERCP, a combination of intravenous mesna plus rectal indomethacin may decrease the PEP rate and severity.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Psychiatry
- Vol. 2025 (1) , 9100558
Potential Drug Interaction Between Liraglutide and Clonazepam: A Case Report
Aviophobia, that is, fear of flying, is a common type of anxiety disorder. Benzodiazepines are used in the treatment of anxiety. Liraglutide is a treatment for obesity or overweight in combination with weight‐related comorbidity. We present the case of a 23‐year‐old woman with overweight and aviophobia, who used clonazepam as antianxious protection when flying. When taking liraglutide shortly before clonazepam the efficacy of clonazepam seemed absent as the patient experienced a panic attack at the airport. This finding suggests that liraglutide may interfere with clonazepam and reduce its effect. Further research is needed to establish this association.
- 1 January 2025
- Published by Wiley in Case Reports in Psychiatry
- Vol. 2025 (1) , 9100558
Open AccessPotential Drug Interaction Between Liraglutide and Clonazepam: A Case Report
Aviophobia, that is, fear of flying, is a common type of anxiety disorder. Benzodiazepines are used in the treatment of anxiety. Liraglutide is a treatment for obesity or overweight in combination with weight‐related comorbidity. We present the case of a 23‐year‐old woman with overweight and aviophobia, who used clonazepam as antianxious protection when flying. When taking liraglutide shortly before clonazepam the efficacy of clonazepam seemed absent as the patient experienced a panic attack at the airport. This finding suggests that liraglutide may interfere with clonazepam and reduce its effect. Further research is needed to establish this association.
- Open Access
- 10 February 2024
- Published by Brieflands in Journal of Cellular & Molecular Anesthesia
- Vol. 9 (1)
Effect of CoQ10 Addition to Rectal Indomethacin on Clinical Pancreatitis and Related Biomarkers in Post-endoscopic Retrograde Cholangiopancreatography
Background: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most prevalent complication of ERCP. Oxidative stress has been mentioned as a cause of PEP. Objectives: As preclinical and clinical studies have shown that CoQ10 has anti-inflammatory and antioxidant effects, the present study was designed to examine whether oral CoQ10 addition to rectal indomethacin decreases the rate/severity of PEP. Methods: A prospective double-blind clinical study was done on 347 patients undergoing ERCP. All participants received 100 mg rectal indomethacin just before ERCP. Also, patients were asked to consume CoQ10 (200 mg) or an identical placebo for 1 h before the procedure. The occurrence and severity of PEP were determined in the participants. The levels of amylase, lipase, and malondialdehyde (MDA) were also measured 12 h after ERCP. Results: The total rate of PEP was equal to 12.1% in intention-to-treat (ITT) and 13% in per-protocol (PP) analyses. A meaningful difference was observed in the rate and severity of PEP between the CoQ10 and placebo arms (9.8% vs 14.4% in ITT and 10.2% vs 15.1% in PP, sequentially). Secondary levels of amylase, lipase, and MDA were lower in the CoQ10 arm than in the placebo arm (P = 0.032, 0.022, and 0.036, sequentially). Conclusions: A combination of oral CoQ (200 mg) plus rectal indomethacin (100 mg) could decrease the PEP rate and severity meaningfully compared to the use of indomethacin alone.
- 10 February 2024
- Published by Brieflands in Journal of Cellular & Molecular Anesthesia
- Vol. 9 (1)
Open AccessEffect of CoQ10 Addition to Rectal Indomethacin on Clinical Pancreatitis and Related Biomarkers in Post-endoscopic Retrograde Cholangiopancreatography
Background: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most prevalent complication of ERCP. Oxidative stress has been mentioned as a cause of PEP. Objectives: As preclinical and clinical studies have shown that CoQ10 has anti-inflammatory and antioxidant effects, the present study was designed to examine whether oral CoQ10 addition to rectal indomethacin decreases the rate/severity of PEP. Methods: A prospective double-blind clinical study was done on 347 patients undergoing ERCP. All participants received 100 mg rectal indomethacin just before ERCP. Also, patients were asked to consume CoQ10 (200 mg) or an identical placebo for 1 h before the procedure. The occurrence and severity of PEP were determined in the participants. The levels of amylase, lipase, and malondialdehyde (MDA) were also measured 12 h after ERCP. Results: The total rate of PEP was equal to 12.1% in intention-to-treat (ITT) and 13% in per-protocol (PP) analyses. A meaningful difference was observed in the rate and severity of PEP between the CoQ10 and placebo arms (9.8% vs 14.4% in ITT and 10.2% vs 15.1% in PP, sequentially). Secondary levels of amylase, lipase, and MDA were lower in the CoQ10 arm than in the placebo arm (P = 0.032, 0.022, and 0.036, sequentially). Conclusions: A combination of oral CoQ (200 mg) plus rectal indomethacin (100 mg) could decrease the PEP rate and severity meaningfully compared to the use of indomethacin alone.